ArticleBMC gastroenterology2026
Profile and diagnostic value of N6-methyladenosine-related mRNA regulators in colorectal adenoma and colorectal cancer.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundN6-methyladenosine (m6A) modification is a key epigenetic modification involved in many diseases. However, the roles of m6A regulators in the progression of colorectal adenoma (CRA) or colorectal cancer (CRC) are still unclear fully.
methodsGene expression profiles were obtained from the Gene Expression Omnibus (GEO) datasets GSE41657, GSE100179, and GSE117606. We analyzed differentially expressed m6A (DE-m6A) regulators and obtained two m6A patterns of CRA and CRC using the consensus clustering based on DE-m6A regulators. The differentially expressed genes (DEGs) between m6A patterns were subjected to gene set enrichment analysis (GSEA), and the m6A-related hub genes were evaluated by protein‒protein interaction (PPI) analysis. We screened important DE-m6A regulators using least absolute shrinkage and selection operation (LASSO) regression and support vector machine-recursive feature elimination (SVM-RFE) algorithms. Receiver operating characteristic (ROC) curve was applied to analyze the clinical diagnostic value of hub genes and DE-m6A regulators, which were verified using quantitative real-time PCR.
resultsFifteen DE-m6A regulators between controls and CRA patients and thirteen DE-m6A regulators between controls and CRC patients were identified with difference statistically. Two m6A patterns were obtained for CRA and CRC patients via consensus clustering based on DE-m6A regulators. DEGs were enriched in ribosomal structural components, signal receptor regulation, and mitochondrial structure and function. The five hub genes included TP53, EEF1A1, TBP, MARS1 and CCT7 in CRA, none in CRC were screened. Hub genes had good predictive effects on CRA and CRC. Six important DE-m6A regulators in CRA and one in CRC were screened out, and YTHDF1 on CRA or CRC, HNRNPA2B1 in only CRC had high diagnostic efficacy. Six important DE-m6A regulators were verified using quantitative real-time PCR.
conclusionsThe m6A-related regulatory mode might have more important diagnostic value in CRA than in CRC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.